SCHEMBL19658653

SCHEMBL19658653

CC(=O)N1CCC(n2cnc3ccccc32)CC1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.65
KMT2A Q03164 1/20 0.62
DRD2 P14416 1/20 0.60
SLC6A4 P31645 1/20 0.60
ALDH1A1 P00352 1/20 0.60
OPRM1 P35372 1/20 0.56
OPRL1 P41146 1/20 0.56
FPR2 P25090 1/20 0.54
PKM P14618 1/20 0.53
BRD4 O60885 1/20 0.50
PRMT5 O14744 2/20 0.47
WDR77 Q9BQA1 2/20 0.47
HSD17B10 Q99714 1/20 0.45
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
IKZF3 Q9UKT9 1/20 0.45
GAA P10253 1/20 0.45
CCR5 P51681 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1834469 0.87 USP2 (0.63) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL13853782 0.85 USP2 (0.71) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL19652153 0.85 USP2 (0.61) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL19658662 0.83 USP2 (0.59) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL6246964 0.82 HCAR1 (0.59) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL15825127 0.82 USP2 (0.47) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL3730443 0.81 DRD2 (0.72) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL13155876 0.81 USP2 (0.56) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL432010 0.80 DRD2 (0.65) USP2KMT2ADRD2SLC6A4ALDH1A1
SCHEMBL13801310 0.78 DRD2 (0.60) USP2KMT2ADRD2SLC6A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 USP2 3360/4885KMT2A 165/4885DRD2 2016/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 USP2 3360/4885KMT2A 165/4885DRD2 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.